8AURICH-BARRERA B, WILTON L, BROWN D, et al. Paediatric postmarketing pharmacovigilance using prescription-event monitoring: comparison of the adverse event profiles of lamotriglne prescribed to children and adults in England [ J ]. Drug Saf,2010,33 (9) :751-763.
9HIRSEH L, CLASSEN J A, BUEHSBAUM R, et al. Predicting rash from lamotrigine :results from review of 812 patients [ J ]. Epilepsia ,2003 ,44 ( Suppl 9) :277.
6Ren S. Determination of lamotrigine in biologic material by a simple and rapid liquid chromatography method. Ther Drug Monit, 1998, 20(2) :209.
7Reunanen A. Ramdom open multicenter compatative trial of lamotrigine and cabamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res, 1996, 23 (2): 149.
8Brodie M. Double blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet, 1995, 345 (8948) :476.
9May TW, Rambeck B, Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit, 1996,18 (5) :523.
10Armijo A, Bravo J, Cuadrado A. Lamotrigine serum concentrationto - dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit, 1999, 21(2) :182.
